| Item 3.01 | Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
The information in Item 5.07 of this Current Report on Form 8-K under the heading “Appointment of Director/Nasdaq Listing Rule 5605(c)(2)” as it relates to the audit committee (“Audit Committee”) of the board of directors (the “Board”) of Delcath Systems, Inc. (the “Company”) is hereby incorporated by reference in this Item 3.01.
| Item 5.02 | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Omnibus Equity Incentive Plan
At the 2024 annual meeting of stockholders held on May 23, 2024 (the “Annual Meeting”), the stockholders of the Company approved an amendment to the Company’s 2020 Omnibus Equity Incentive Plan (the “2020 EIP”) to increase by 2,000,000 the number of shares of the Company’s common stock, $0.01 par value (the “Common Stock”) available thereunder.
A more detailed summary of the material features of the 2020 EIP, as amended, including the terms of stock option grants thereunder, is set forth in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 12, 2024 (the “2024 Proxy Statement”). That summary and the foregoing description are qualified in their entirety by reference to the text of the 2020 EIP, as amended, which is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Appointment of Director/Nasdaq Listing Rule 5605(c)(2)
Following the voting on Proposal 1 (as listed below in Item 5.07) at the Annual Meeting on May 23, 2024, Roger Stoll’s previously announced retirement from the Board took effect. On March 24, 2024, the Company notified The Nasdaq Stock Market LLC (“Nasdaq”) of the retirement of Roger Stoll from the Board and the Audit Committee. With Dr. Stoll’s retirement the Audit Committee currently is comprised of only two qualified Directors. Pursuant to Nasdaq Listing Rule 5605(c)(2), the Audit Committee must be comprised of at least three qualified Directors. On May 29, 2024, the Company received notice from Nasdaq confirming that the Company was no longer in compliance with such Nasdaq Listing Rule. The Company intends to fill the vacancy on the Audit Committee as expeditiously as possible. The Company is entitled to a cure period to regain compliance with Nasdaq Listing Rule 5605(c)(2)(A) until the earlier of the Company’s next annual meeting or May 23, 2025. The Company will regain compliance with the audit committee composition requirements of Nasdaq Listing Rule 5605(c)(2)(A) by the end of the cure period.
Additionally, in connection with Roger Stoll’s retirement from the Company’s Board, on May 23, 2024, the Company appointed Bridget Martell, M.A. M.D., as a Class III Director on the Company’s Board, commencing on May 23, 2024 and continuing until her term on the Board expires at the Company’s 2027 Annual Meeting.
At this time, Dr. Martell has not been named to any committees of the Board. There are no arrangements or understandings between Dr. Martell and any other persons pursuant to which she was elected as a director, and there are no transactions between Dr. Martell and the Company that would be required to be reported under Item 404(a) of Regulation S-K.
A copy of the Company’s press release related to Dr. Martell’s appointment to the Board is attached as Exhibit 99.1 to this Current Report on Form 8-K.
| Item 5.07 | Submission of Matters to a Vote of Security Holders |
At the Annual Meeting, the Company’s stockholders voted on four proposals, each of which is described in more detail in the 2024 Proxy Statement. Of the 27,433,579 shares of the Common Stock outstanding and convertible preferred stock eligible to vote as of the record date, 18,089,113 shares, or approximately 65.94%, were present or represented by proxy at the Annual Meeting.
